Cannabis Extract for Post-Surgical Pain: Clear Dose-Response But Trial Stopped Over Safety Concern | Research

The takeaway

A dose-escalation trial of oral cannabis extract for post-operative pain found significant dose-related reductions in rescue analgesia needs (100% at 5mg, 50% at 10mg, 25% at 15mg), but the study was terminated after a serious vasovagal event at the highest dose.

Read this if you want to understand clinical trial evidence for cannabis as a post-surgical pain reliever.

Rescue analgesia needed by 100% at 5mg, 50% at 10mg, 25% at 15mg (P < 0.001 trend)

What the researchers found

Patients were given a single dose of 5, 10, or 15 mg of oral cannabis extract (Cannador) for post-operative pain after stopping patient-controlled analgesia. The dose-response relationship was clear and significant.

All 11 patients (100%) receiving 5 mg requested rescue analgesia. At 10 mg, 15 of 30 patients (50%) needed rescue medication. At 15 mg, only 6 of 24 patients (25%) needed rescue (log rank test for trend P < 0.001). The number needed to treat to prevent one rescue request was 2.0 for 10 mg and 1.3 for 15 mg, comparable to many routinely used analgesics.

However, there were significant trends for increasing sedation (P = 0.03) and more adverse events (P = 0.002) at higher doses. The study was terminated after a serious vasovagal adverse event in a patient receiving the 15 mg dose.

Why it matters

The clear dose-response relationship and competitive number needed to treat values provided strong evidence for cannabinoid analgesic efficacy. However, the safety-related termination highlights the challenge of finding the right dose: effective pain relief required doses that also produced more adverse events.

The numbers in context

5 mg: 100% needed rescue (11/11). 10 mg: 50% needed rescue (15/30). 15 mg: 25% needed rescue (6/24). Trend: P < 0.001. NNT to prevent rescue: 2.0 (10 mg), 1.3 (15 mg). Increasing sedation: P = 0.03. More adverse events: P = 0.002. Study terminated: serious vasovagal event at 15 mg.

How the study worked

Multi-center dose-escalation study. Patients aged 18-75 received a single dose of 5, 10, or 15 mg Cannador after stopping patient-controlled analgesia for at least moderate pain. Dose escalation based on rescue analgesia requests and adverse effects. Pain relief, pain intensity, and side effects recorded over 6 hours.

What this study cannot tell us

Study terminated early due to adverse event, limiting the total evidence base. Single-dose design cannot assess effects of repeated dosing. The dose-escalation design means treatment groups were not concurrent. The vasovagal event may or may not have been drug-related.

How to read the evidence

Randomized dose-escalation trial published in Anesthesiology. Clear dose-response but terminated early due to safety concerns, limiting conclusions about the optimal therapeutic window.

When this study was published

Published in 2006 in Anesthesiology. Cannabis-based analgesic research has continued, with more emphasis on non-oral delivery methods and combination products.

The bigger picture

This trial demonstrated that cannabis-based analgesics can be effective but face the same dose-limiting side effect challenge as many other pain medications. The NNT values were comparable to established analgesics, suggesting cannabinoids could be competitive if safety margins can be improved.

Questions still open

Can the analgesic dose be separated from the adverse event dose through different formulations or delivery methods? How do these cannabinoid NNT values compare to the specific analgesics these patients would otherwise receive?

Common questions

Can cannabis extract relieve post-surgical pain?

This trial showed clear dose-related pain relief: at the 15 mg dose, only 25% of patients needed additional pain medication, compared to 100% at 5 mg. The number needed to treat was comparable to many standard analgesics. However, higher doses also produced more sedation and adverse events.

Why was the trial stopped?

The study was terminated after a patient receiving the 15 mg dose experienced a serious vasovagal event (a sudden drop in heart rate and blood pressure). While it is unclear if this was definitively drug-related, the safety concern warranted stopping the trial.

Read the original research

A multicenter dose-escalation study of the analgesic and adverse effects of an oral cannabis extract (Cannador) for postoperative pain management.

Anesthesiology, 104(5), 1040-6

View on PubMed ↗

Citation

Holdcroft, Anita; Maze, Mervyn; Doré, Caroline; Tebbs, Susan; Thompson, Simon. (2006). A multicenter dose-escalation study of the analgesic and adverse effects of an oral cannabis extract (Cannador) for postoperative pain management.. Anesthesiology, 104(5), 1040-6.